The promise is real, but clinical readiness is not: Preclinical and early human data are compelling, but without large-scale trials, validated delivery methods, and long-term safety data, Epitalon remains an experimental peptide, one to watch closely, but not yet ready for mainstream clinical adoption
We have observed a homeostatic imbalance of purine catabolism in first-episode neuroleptic-nave patients with SZ (FENNS)
The Outperform clinical trial program gives compelling prove of tirzepatide's preferences over conventional treatments
This article summarizes topical peptides with proven efficacy in controlled in vivo studies
Biotechnology & Biotechnological Equipment, 29(2), 205220
For those with B12 deficiency symptoms, these injections can significantly elevate overall wellness and vitality